

21 June 2007

To All Pharmaceutical Suppliers, Hospital Pharmacists, Medical
Groups and Interested Parties

Consultation on a proposal to list metoprolol succinate (Metoprolol-AFT CR) in the Pharmaceutical Schedule

PHARMAC has entered into a provisional agreement with AFT Pharmaceuticals Ltd in relation to the listing of metoprolol succinate sustained release tablets (Metoprolol-AFT CR) in the Pharmaceutical Schedule. Metoprolol-AFT CR is currently unregistered. Details of the proposal are as follows:

- Subject to gaining all necessary consents, Metoprolol-AFT CR would be listed, as soon as practicable, in Section B and in Part II of Section H of the Pharmaceutical Schedule at the following prices and subsidies (ex-manufacturer, excluding GST):

Chemical	Presentation	Strength	Brand	Pack Size	Price and subsidy
Metoprolol Succinate	Sustained release tablet	23.75 mg	Metoprolol-AFT CR	30	\$2.73
Metoprolol Succinate	Sustained release tablet	47.5 mg	Metoprolol-AFT CR	30	\$3.41
Metoprolol Succinate	Sustained release tablet	95 mg	Metoprolol-AFT CR	30	\$5.88
Metoprolol Succinate	Sustained release tablet	190 mg	Metoprolol-AFT CR	30	\$10.63

- Metoprolol-AFT CR would be protected from delisting and reference pricing until 30 June 2009.

PHARMAC welcomes feedback on this proposal. If you wish to make comments regarding this proposal for the PHARMAC Board to consider when making its decision, please forward them to Stephen Woodruffe at PHARMAC by **5:00 pm, Wednesday, 11 July 2007**. If you have any questions regarding this proposal, please contact me on (04) 916 7555 or Stephen.Woodruffe@PHARMAC.govt.nz.

Yours sincerely



Stephen Woodruffe
Therapeutic Group Manager